Pharmaceuticals, Biotechnology and Life Sciences
The European Commission (EC) approved Sanofi’s Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.…
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
Glenmark Pharmaceuticals won Orphan Drug Designation from USFDA to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior therapies.
DUBLIN–(BUSINESS WIRE)–The “Multiple Myeloma: Epidemiology Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. In 2017, the 8MM had…
PRIME (PRIority MEdicines) designation based on clinical study results evaluating safety and efficacy of novel CAR-T therapy in the treatment…
Successful manufacturing and release of GMP vials of UCARTCS1 NEW YORK–(BUSINESS WIRE)–Regulatory News: Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS),…
First DARZALEX combination regimen being pursued as frontline treatment option for transplant eligible patients with multiple myeloma BEERSE, Belgium–(BUSINESS WIRE)–The…
Amgen posted positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three years after enrollment.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.
Health Canada has accepted for review Janssen’s new drug submission (NDS) for daratumumab for treatment of Multiple Myeloma.